Triiodothyronine supplementation and cytokines during cardiopulmonary bypass in infants and children  by Priest, James R. et al.
Perioperative Management Priest et al
P
MTriiodothyronine supplementation and cytokines during
cardiopulmonary bypass in infants and childrenJames R. Priest, MD, MA,a,b April Slee, MS,c Aaron K. Olson, MD,a Dolena Ledee, PhD,a
Fionnuala Morrish, PhD,d and Michael A. Portman, MDaFrom th
Divis
cile P
and F
This res
Admi
R-197
Awar
sourc
King
Disclosu
Receive
for pu
Address
1900
org).
0022-52
Copyrig
doi:10.1
938Objective: The Triiodothyronine Supplementation in Infants and Children Undergoing Cardiopulmonary
Bypass (TRICC) study demonstrated a shortened time to extubation in children younger than 5 months old un-
dergoing cardiopulmonary bypass for congenital heart surgery with triiodothyronine supplementation. Cardio-
pulmonary bypass precipitates a systemic inflammatory response that affects recovery, and triiodothyronine is
related to cytokine mediators of inflammation. We sought to investigate the preoperative cytokine levels by age
and relationship to the triiodothyronine levels and to examine the effect of the cytokine levels on the time to
extubation.
Methods: We measured 6 cytokines at preoperative time 0 and 6 and 24 hours after crossclamp removal in 76
subjects.
Results: The preoperative cytokine levelswere related to both the triiodothyronine levels and the patient age. The
postoperative cytokine levelswere predictive of the triiodothyronine levels at 6, 12, 24, and 72 hours. Preoperative
CCL4 was associated with an increased chance of early extubation. Inclusion of the cytokines did not change the
relationship of triiodothyronine to the time to extubation, and the postoperative course of interleukin-6 was in-
dependently associated with a decreased chance of early extubation.
Conclusions: The preoperative and postoperative cytokine levels, in particular, interleukin-1b, showed
complex time-dependent relationships with triiodothyronine. The data suggest that cytokine-mediated suppres-
sion of triiodothyronine plays an important role in determining the clinical outcome after cardiopulmonary by-
pass. (J Thorac Cardiovasc Surg 2012;144:938-43)Supplemental material is available online.
Since the development of cardiopulmonary bypass (CPB) in
the 1950s, its use has been associated with an inflammatory
response, although early reports attributed the pathologic
and radiologic findings of lung injury to anoxia or inade-
quate perfusion.1 Later investigations associated CPB
with complement activation, immunoglobulin deficiency,
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The Journal of Thoracic and Cardiovascular Surgimmunologic perturbation.2,3 Contemporary research has
demonstrated a clear CPB-related inflammatory response,
induced by the synthetic milieu of the bypass apparatus,
with a presumed clinical effect on the postoperative out-
comes in pediatric and adult populations.2-4 Research into
ameliorating this CPB-related inflammatory response has
spanned the disciplines of anesthesia, perfusion, surgery,
pharmacology, and critical care.5-9
Recently we conducted the Triiodothyronine (T3)
Supplementation in Infants and Children Undergoing
Cardiopulmonary Bypass (TRICC) study in a pediatric
population requiring congenital heart surgery.10 The TRICC
study concluded that T3 supplementation shortened the time
to extubation (TTE) and improved cardiac function in chil-
dren younger than 5 months old. A systematic review of T3
supplementation in the postoperative care of adults undergo-
ing a variety of surgeries concluded that T3 improves the
postoperative cardiac index.11 In adults with dilated cardio-
myopathy, T3 supplementation improved the neuroendo-
crine hormone levels and measures of cardiac output.12
Some published data have suggested that cytokines might
interact with the thyroid hormone axis. In the myocardium,
evidence has shown that T3 directly modulates transcrip-
tional regulation, histone modification, ion channels, and in-
tracellular cations.13-15Additional observational studies have
suggested an effect of T3 outside the myocardium, reportingery c October 2012
Abbreviations and Acronyms
ANCOVA ¼ analysis of covariance
CI ¼ confidence interval
CPB ¼ cardiopulmonary bypass
IL ¼ interleukin
MCP1 ¼ monocyte chemotactic protein-1
T3 ¼ triiodothyronine
TRICC ¼ Triiodothyronine Supplementation in
Infants and Children Undergoing
Cardiopulmonary Bypass
TTE ¼ time to extubation
Priest et al Perioperative Managementan inverse relationship between the pro-inflammatory cyto-
kine interleukin (IL)-6 and T3 levels in the setting of CPB
and infectious diseases in pediatric populations.16,17
Infusion of recombinant IL-6 into healthy adults has been
shown to decrease T3 levels at 24 hours after infusion.18
We sought to explore the relationship of age and T3 sup-
plementation to cytokine levels and outcomes in a subset of
the TRICC cohort. The primary objectives of the present
study were to investigate the preoperative cytokine levels
by age and relationship to the T3 levels and to examine
the pre- and postoperative cytokine levels for their effect
on the TTE.P
MMETHODS
Study Population
The study population has been previously described in detail in the
TRICC report.10 In brief, of the 193 participants younger than 2 years
old undergoing CPB for congenital heart surgery, we selected a subset
for cytokine analysis. Patients were previously categorized as being at
high or low risk according to an Aristotle score cutoff of 10, and the study
included patients with a hypoplastic left heart. After enrollment, we ran-
domized the participants to treatment with T3 or placebo using a complex
stratification algorithm that was block randomized by surgical diagnosis.
Also, patients received routine postoperative care by critical care physi-
cians whowere unaware of the treatment assignment. Steroid use varied ac-
cording to the standard clinical protocols in use at the different institutions.
We summarized the baseline characteristics of the cytokine subset alone by
treatment status. Of the 193 participants in the TRICC cohort, we included
the first 65 participants enrolled as a subset for cytokine analysis and an ad-
ditional 11 with available serum to balance the risk and demographics. The
institutional review boards at all participating centers approved the present
study, and the parents of all participants provided written informed consent.
Laboratory Testing
Blood was sampled at 3 points: preoperative time 0 (before administra-
tion of T3) and 6 and 24 hours after crossclamp removal. Sampling involved
multiplex measurement of 6 cytokines in a commercially available kit (IL-
1b, IL-6, IL-8, IL-10, CCL4, andmonocyte chemotactic protein-1 [MCP1],
which bind to 4 different receptor classes involved in vascular inflamma-
tion).19 Frozen human serum at80C was thawed on ice and tested to as-
sess the levels of 6 different cytokines. The cytokines were measured using
the Bio-Plex ProHumanCytokineAssay bead kit (Bio-RadLaboratories,
Hercules, Calif). The beads were added to wells with serum samples andThe Journal of Thoracic and Caincubated for 30 minutes. After incubation, the plates were washed and de-
tection antibodies were added. After additional incubations and washes, the
plates were run immediately on a Luminex 200 System (Luminex Corpo-
ration, Austin, Tex) with data acquisition andMasterPlex analysis software
(Hitachi Solutions America, South San Francisco, Calif).
Statistical Analysis
We used the R language and environment for statistical computing, ver-
sion 2.8.1 (R Foundation for Statistical Computing, Vienna, Austria) and
SAS (SAS Institute, Cary, NC) for all statistical analysis. Graphs were pro-
duced using Splus, version 6.2 (Tibco Software, Palo Alto, Calif). We did
not perform correction for tests of multiple hypotheses. Patients who died
or experienced an otherwise catastrophic outcome were excluded. For all
analyses involving cytokine levels or T3, we transformed the raw values us-
ing the natural logarithm of the raw value þ1. Unless otherwise stated, the
T3 and cytokine values were analyzed on the transformed scale to account
for heavily skewed distributions to maintain a constant variance for regres-
sion modeling and statistical tests. We tested the relationships between age
and risk using a Wilcoxon rank sum test and investigated the association
between age and cytokine levels with linear least squares regression at
baseline time 0 for each cytokine. As suggested by previous investigators,
we also analyzed the IL-10/IL-6 ratio in our analyses of age.20
We examined the preoperative relationship of T3 and cytokines with an
analysis of covariance (ANCOVA) model that included all cytokines and
the Aristotle risk class to account for the randomization stratification.
High risk was determined by an Aristotle score greater than 10. The post-
operative ANCOVA models included the cytokine levels at hour 6 and risk
as predictor variables for T3 levels at 6, 12, 24, and 72 hours. To determine
the natural relationship of the preoperative cytokine levels to the TTE, we
included only the placebo patients in a Cox proportional hazards model.
The outcome was extubation, and patients were censored at death or 7
days after intubation. To analyze the relationship of the cytokine response
to TTE, we constructed a Cox proportional hazards model that included the
time-dependent cytokine levels and time-dependent T3 levels to account
for treatment. As a sensitivity analysis, the treatment assignment was added
to this model. The covariates for ANCOVA and Cox proportional hazards
models were chosen using stepwise selection to select the most important
predictors for each outcome variable.
RESULTS
Patient Characteristics
Analysis of the patient demographics of the 76 partici-
pants within the cytokine subset and the remainder of the
TRICC cohort was performed and identified the cytokine
subset as younger, with greater risk and with elevated base-
line T3 levels (Table E1).Within the cytokine subset, no sta-
tistically significant differences were found in the baseline
characteristics when analyzed by treatment status. How-
ever, 5 more high-risk patients were in the treated group
of the cytokine subset (Table 1). Risk was inversely related
to age (Wilcoxon rank sum test, P<.001). Figure 1 displays
a graph of the mean values and standard errors for the 6 cy-
tokines over time in the placebo group. IL-6, IL-8, and IL-
10 were significantly increased after CPB at both 6 and 24
hours in the placebo group (Figure 1 and Table E2).
Cytokines and Age
The baseline levels of IL-6 (1.11 pg/dL for each month
of age; 95% confidence interval [CI], 0.84 to 1.03;
P ¼ .005), IL-8 (1.06 pg/dL for each month of age; 95%rdiovascular Surgery c Volume 144, Number 4 939
TABLE 1. Baseline characteristics of analyzed cytokine subset
stratified by treatment status
Characteristic
Placebo
(n ¼ 37)
Triostat
(n ¼ 39)
P
value
Male gender (n) 15 15 .96
Risk stratification (n) .45
High 13 18
Low 24 21
Age (mo) .69
Median 4.1 3.4
Range 0-23.2 0-19.1
Baseline triiodothyronine (U) 172 188 .19
Mean intubation time (h) 94 113 .67
Mean crossclamp time (min) 62 61 .96
Mean bypass time (min) 97 97 1.00
Deaths (n) 1 3 .64
All P values presented were derived from Student t test, except for gender, risk strat-
ification, and death, which were derived from a simple chi-square test.
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MCI,1.12 to1.01; P ¼ .033), and CCL4 (1.06 pg/dL for
each month of age; 95% CI, 1.10 to 1.03; P ¼ .001)
showed inverse relationships with months of age and IL-
10 (1.05 pg/dL for each month of age; 95% CI, 1.01-
1.47; P ¼ .05) showed a trend toward a direct relationship
with age (Figure 2). At baseline (time 0), IL-1b and
MCP1 did not show statistically significant relationships
with age; however, the IL-10/IL-6 ratio was directly related
to age (1.06 U/month of age; 95% CI, 1.03-1.08; P<.001).
Cytokines and T3
Because of the preprocedure homogeneity of the cohort,
we used all patients in an ANCOVAmodel to determine the
relationship between baseline risk and cytokine levels and
baseline T3 (Figure 3). We found several measures to be in-
versely related to the baseline T3 level, including high-riskIL6 over time
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FIGURE 1. Cytokine levels during time course of the trial in placebo patien
(C-C motif) ligand 4; MCPI, monocyte chemotactic protein-1.
940 The Journal of Thoracic and Cardiovascular Surgstatus (1.46 log T3 ng/dL for high-risk status; 95% CI,
1.70 to 1.25; P< .001), IL-6 (1.08 log T3 ng/dL per
ng/dL of IL-6; 95% CI, 1.16 to 1.01; P  .001), and
IL-1b (1.45 log T3 ng/dL per ng/dL of IL-1b; 95% CI,
1.82 to1.16; P ¼ .002). In addition, we found a direct re-
lationship between IL-8 and baseline T3 (1.11 log T3 ng/dL
per ng/dL of IL-8; 95% CI, 1.03-1.19; P ¼ .004).
We used ANCOVA to examine the relationships between
cytokines and T3. In the placebo patients, we modeled all
cytokines at 6 hours after crossclamp removal (the earliest
postoperative measure) versus the T3 levels at 6 hours
and determined that risk status, IL-1b, and IL-10 were sig-
nificantly associated with the T3 levels. Only IL-1b at 6
hours was inversely associated with the T3 levels at all
points through 72 hours. IL-10 at 6 hours was inversely as-
sociated with the T3 levels at 12 and 24 hours, and high-risk
status was inversely associated with the T3 levels at 6 hours
(Figure 4 and Table E3).Cytokines and Clinical Parameters
Preoperative IL-8 was associated with a decreased
chance of early extubation (hazard ratio, 0.21; 95% CI,
0.06-0.78; P¼ .02), and preoperative CCL4 was associated
with an increased chance of early extubation (hazard ratio,
1.51; 95% CI, 1.11-2.06; P ¼ .001; Figure E1).
Among all patients, modeling T3, IL-6, and CCL4 as
time-dependent covariates, greater IL-6 levels were associ-
ated with a reduced chance of early extubation (hazard ra-
tio, 0.70; 95% CI, 0.57-0.85; P < .001), as was the
baseline high-risk status (hazard ratio, 0.47; 95% CI,
0.26-0.85; P ¼ .01). High T3 levels were associated with
an increased chance of early extubation (hazard ratio,
1.43; 95% CI, 1.25-1.63; P< .001), as were high CCL4
levels (hazard ratio, 1.34; 95% CI, 0.97-1.85; P ¼ .08;ver time
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FIGURE 2. Preoperative interleukin-6, interleukin-8, and CCL4 levels were inversely related to patient age (n ¼ 76). IL, Interleukin; CCL4, chemokine
(C-C motif) ligand 4.
Priest et al Perioperative Management
P
MFigure 5). These results were similar when randomization
assignment was added to the model.
DISCUSSION
The major objective of the present study was to define the
relationships among T3, cytokine levels, and the clinical
outcomes in the study population of children undergoing
CPB. As would be expected from our previously reported
trial data, the T3 level throughout the early postoperative
period is a powerful predictor of the TTE. We observed
complex pre- and postoperative relationships among the
measured cytokines, thyroid hormone levels, and the TTE.
In our analysis of cytokines and age, younger patients had
greater levels of the pro-inflammatory cytokines IL1b, IL-6,
and IL8 and a lower level of the anti-inflammatory IL-10/
IL-6 ratio than the older patients (Figure 2). In aggregate,
these finding might imply that younger patients undergoing-0.8 -0.6 -0.4 -0.2 0 0.2 0.4 0.6 0.8
High Risk***
Baseline Log IL6*
Baseline Log IL8**
Baseline Log IL1B**
Regression coefficient and 95% CI
FIGURE 3. Forest plot of b-coefficients from linear regression analysis of
baseline cytokine levels and baseline triiodothyronine levels (n¼ 37). *P<
.05; **P<.01; ***P<.001. IL, Interleukin; CI, confidence interval.
The Journal of Thoracic and Caheart surgery have a pro-inflammatory cytokine profile that
diminishes with age. As expected, risk and age were also in-
versely related. Little is known about the steady-state cyto-
kine levels of healthy or ill neonates, and our small cohort
and study design were not suited to evaluate whether the
pro-inflammatory cytokine profile of the younger patients
was independent from their greater preoperative risk or con-
genital cardiac lesion.
Although we did not observe a relationship between the
preoperative T3 level and TTE, we did note that the 2 pre-
operative cytokines related to TTE—IL-8 and CCL4—both
bind chemokine receptors. The chemokines and their recep-
tors are known to regulate leukocyte trafficking and migra-
tion in the setting of myocardial inflammation, which might
suggest a process by which the cytokine levels influence
myocardial function in the pre- and postoperative periods.21
Additionally, we found relationships among IL-1b, IL-8,
and T3 at baseline. This finding highlights the complex re-
lationship between cytokines and the endogenous levels of
T3 that was the very subject of our study intervention. The
inverse relationship of IL-1b to the preoperative T3 level is
of particular interest given the observation that IL-1b
suppresses the secretion of thyroid-stimulating hormone
from cultured rat anterior pituitary cells.22 Allan and col-
leagues23 did not detect significant levels of IL-1b pre- or
postoperatively in another population of young infants
and children undergoing CPB. This contrasting finding
might reflect differences in the study methods such as their
use of a protein microarray chip versus our multiplex
method or might have been due to experimental error.23
The preoperative findings might thus serve to illustrate the
steady-state relationship between cytokines and the thyroid
hormone axis, which is then altered by administration of T3.rdiovascular Surgery c Volume 144, Number 4 941
FIGURE 4. Forest plot of b-coefficients from linear regression analysis of 6-hour cytokine levels and triiodothyronine levels at 6, 12, 24, and 72 hours
postoperatively (n ¼ 37). *P<.05; **P<.01; ***P<.001. IL, Interleukin.
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P
MConsistent with the preoperative observation of an inverse
relationship between IL-1b and T3 and the experimental
data noted, T3 exhibited sensitivity to the IL-1b levels
throughout the first 72 hours of the postoperative period
(Figure 4). Considering the pre- and postoperative data to-
gether suggest that the improved TTE observed in
patients treated with T3 results from the repletion of the
T3 suppressed in patients with elevated IL-1b. As a time-
dependent covariate, IL-6 was predictive of prolonged extu-
bation. TheCox proportional hazardmodel that included the
postoperative T3 level as a continuous variable instead of
treatment status suggested that the serum levels of T3 cap-
tures most of the effect of treatment.
Anecdotally, clinicians have used T3 postoperatively for
decades in patients slower to recover from CPB than ex-
pected or who display signs of low cardiac output0.5 1 1.5 2 2.5 3
Hazard Ratio & 95% CI
High Risk*
Time dependent Log  IL6***
Time dependent Log CCL4
Time dependent Log T3***
FIGURE 5. Forest plot of hazard ratio for time to extubation of time-
dependent cytokine levels, time-dependent triiodothyronine level, and
risk (n ¼ 76). *P<.05; ***P<.001. T3 is scaled by 5. IL, Interleukin;
CCL4, chemokine (C-C motif) ligand 4; CI, confidence interval.
942 The Journal of Thoracic and Cardiovascular Surgsyndrome. Our data suggest that preoperative screening of
certain cytokines, such as IL-6, IL-8, or CCL4, could help
in the risk stratification of patients at risk of prolonged intu-
bation. With regard to T3 treatment, using pre- and postop-
erative IL-1b levels might add predictive value to
determining which patients could benefit from postopera-
tive T3 supplementation.
The choice of cytokines was determined by the multiplex
chips commercially available at the initial study. The chosen
platform of assayed cytokines included both IL-6 and IL-10,
which were reasonable candidates for the study according to
the available data from previous studies. However, an ex-
haustive list of cytokines and their various isoforms is signif-
icantly larger than the 6 cytokines used in our study; thus,
our data could not completely capture the nuanced and com-
plex inflammatory response after CBP and the effect of T3
supplementation. Compared with the overall TRICC cohort,
the cytokine subset was younger, at higher risk, and had el-
evated baseline T3 levels. Althoughwe attempted to account
for the difference between the TRICC cohort and the cyto-
kine subset with multivariate analysis, such techniques can
introduce the possibility of error, which we could not com-
pletely exclude. Finally, the cytokine relationships de-
scribed were based on 76 patients with varying ages and
diagnoses (Table E4); therefore, a larger trial is necessary
to determine the broad applicability of the response of cyto-
kines to CPB and T3 supplementation, particularly for
children younger than 5 months old.CONCLUSIONS
These data reinforce the important association between
T3 and the clinical outcome, TTE, in young patients under-
going CPB. Complex relationships exist between and
among the multiple cytokines, in particular IL-1b, that
vary with time during the postoperative course. Overall,ery c October 2012
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P
Mthese relationships suggest that T3 suppression is influenced
by the cytokine response to both the underlying disease
state and to CPB and that the effect of inflammation on
the TTE can be corrected by T3 supplementation.
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TABLE E1. Baseline characteristics for entire cohort versus cytokine
analysis subset
Characteristic
Cytokine data P
valueNo (n ¼ 117) Yes (n ¼ 76)
Male gender (n) 54 (46%) 30 (39%) .44
Risk stratification .05*
High 31 31
Low 86 45
Age (mo) .04*
Median 5.8 3.6
Range 0-21.7 0-23.2
Baseline triiodothyronine (U) 151 180 <.01*
Mean intubation time (h) 89 104 .56
Mean crossclamp time (min) 62 62 .98
Mean bypass time (min) 99 97 .69
Deaths (n) 4 4 .79
All P values presented were derived from Student t test, except for gender, risk, and
death, which were derived from a simple chi-square test. *Statistical significance
(P  .05).
TABLE E2. Change in cytokine levels in untreated patients after cardiopulmonary bypass at 6 and 24 hours after crossclamping
Variable
Change from baseline to 6 h Change from baseline to 24 h
Patients (n) Mean 95% CI P value Patients (n) Mean 95% CI P value
IL-6 34 2.80 3.23 to 2.37 <.0001* 34 2.83 3.21 to 2.45 <.0001*
IL-8 37 1.11 1.42 to 0.81 <.0001* 37 1.09 1.39 to 0.78 <.0001*
IL-10 32 2.28 2.85 to 1.72 <.0001* 32 0.84 1.26 to 0.41 .0003
IL-1b 33 0.01 0.13 to0.11 .8923 33 0.01 0.09 to0.11 .8586
MCP1 38 0.17 0.03 to0.38 .0956 37 0.12 0.09 to0.32 .2562
MIP1b 38 0.18 0.01 to0.36 .0602 38 0.48 0.30 to0.66 <.0001*
CI, Confidence interval; IL, interleukin; MCP, monocyte chemotactic protein; MIP, macrophage inflammatory protein. *Statistical significance (P  .05).
FIGURE E1. Baseline cytokine values are associated with differences in
the chance of early extubation in untreated patients younger than 5 months
old. *P< .05; **P< .01. CI, Confidence interval; CCL4, chemokine
(C-C motif) ligand 4.
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TABLE E3. Six-hour cytokine levels associated with differences in triiodothyronine levels through 72 hours in untreated patients
Variable DF Parameter estimate SE t value Pr> jtj 95% CI
6-h R-square 0.4441
Intercept 1 5.30402 0.16089 32.97 <.0001 4.97496 to 5.63308
IL-10_6 1 0.06695 0.03475 1.93 .0639 0.13802 to 0.00412
High risk 1 0.28301 0.08473 3.34 .0023 0.45630 to0.10972
IL-1b–6 1 0.39099 0.13190 2.96 .0060 0.66075 to0.12123
12-h R-square 0.3522
Intercept 1 5.20233 0.17535 29.67 <.0001 4.84370 to 5.56097
IL-10_6 1 0.08030 0.03787 2.12 .0427 0.15775 to0.00284
High risk 1 0.15740 0.09235 1.70 .0990 0.34627 to 0.03146
IL-1b–6 1 0.46652 0.14375 3.25 .0030 0.76052 to0.17252
24-h R-square 0.3229
Intercept 1 4.94740 0.17787 27.81 <.0001 4.58361 to 5.31119
IL-10_6 1 0.10474 0.03842 2.73 .0107 0.18331 to0.02617
High risk 1 0.01538 0.09367 0.16 .8707 0.20696 to 0.17620
IL-1b–6 1 0.46901 0.14582 3.22 .0032 0.76724 to0.17079
72-h R-square 0.1996
Intercept 1 5.12113 0.37185 13.77 <.0001 4.34997 to 5.89230
IL-10_6 1 0.08782 0.07566 1.16 .2582 0.24474 to 0.06909
High risk 1 0.08639 0.18143 0.48 .6387 0.46264 to 0.28987
IL-1b–6 1 0.65791 0.28984 2.27 .0334 1.25901 to0.05682
CI, Confidence interval; DF, degrees of freedom; IL, interleukin; SE, standard error.
TABLE E4. Anatomic diagnoses
Isolated ventricular septal defect
Tetralogy of Fallot
Transposition of the great arteries
Hypoplastic left ventricle
Complete atrioventricular canal defect
Total anomalous pulmonary venous drainage
Other low-risk cardiopulmonary bypass
Other high-risk cardiopulmonary bypass
Superior vena cava to pulmonary anastomosis
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